Wk chg

11/11 cls

Inhibitex Inc. (NASDAQ:INHX)

Deutsche Bank

Robyn Karnauskas

Price target




Karnauskas raised her target to $15 from $9 after Inhibitex reported topline data showing that once-daily 200 mg INX-189 as monotherapy reduced median HCV RNA from baseline to day seven by 4.25 log10 IU/mL in the first cohort of a Phase Ib trial in treatment-naive patients with chronic HCV genotype 1 infection (see BioCentury, Nov. 7). She anticipates a 2017 launch of the phosphoramidate nucleoside analog NS5B polymerase inhibitor, with peak annual worldwide sales of $5B.

pSivida Corp. (NASDAQ:PSDV; ASX:PVA)

Ladenburg Thalmann

Juan Sanchez


Neutral (from buy)



Sanchez also removed his target after FDA issued a second complete response for an NDA from partner Alimera Sciences Inc. (NASDAQ:ALIM) for Iluvien to treat diabetic macular edema (DME) associated with diabetic retinopathy. According to Alimera, FDA said the "significant" risks of adverse events in the Phase III FAME trials were not outweighed by the benefits and asked the company to conduct two additional trials to show that Iluvien is safe and effective (see B11). The injectable insert delivers fluocinolone acetonide (FA); Alimera has rights from pSivida